A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Trial Details

NCT ID
NCT07098338
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Rilvegostomig
  • Ramucirumab
  • Dato-DXd
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participant must be ≥ 18 years of age at the time of signing the ICF
  • WHO/ECOG performance status of 0 or 1
  • At least 1 lesion that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline.
  • Adequate bone marrow and organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →